Short answer
OCULAR THERAPEUTIX, INC (OCUL) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $15M (down 5.7% year over year) with net income of −$69M.
Q3 2025 key financials · XBRL
- Revenue
- $15M
- −5.7% YoY · +8.1% QoQ
- Net income
- −$69M
- −90.2% YoY · −2.4% QoQ
- Operating margin
- -472.3%
- EPS (diluted)
- −$0.38
- −81.0% YoY · +2.6% QoQ
Source: XBRL data from the OCULAR THERAPEUTIX, INC (OCUL) Q3 2025 10-Q on SEC EDGAR. USD.
OCULAR THERAPEUTIX, INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No new or materially changed risk factors disclosed in this 10-Q compared to most recent 10-K
- Regulatory compliance risk: insider trading policy enforced with no new Rule 10b5-1 trading plans adopted or terminated during Q3 2025
- Operational risk: potential impact from directors and officers' equity-based compensation transactions governed by strict insider trading policies
- Market risk: reliance on equity awards and open-market transactions by insiders could influence stock liquidity and price volatility
- Financial risk: no disclosed changes in liquidity, debt, or foreign exchange exposure in this filing compared to prior disclosures
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OCULAR THERAPEUTIX, INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.